Wei Wei is currently a full professor and doctoral supervisor at the Institute of Process Engineering (IPE), and the director of key laboratory of biopharmaceutical preparation and delivery, Chinese Academy of Sciences (CAS). In 2004, he graduated from Peking University Health Science Center, and was recommended to IPE for master's and doctor's degree. After graduation in 2011, he continued to work in IPE and received exceptional promotions to associate professor and full professor, successively. His research field mainly focuses on the biomimetic formulation engineering, including the development of new preparation process and the novel design of biomimetic carriers based on natural objects such as protein, bacteria and cells. Upon utilizing the inherent transportation ways, accurate drug delivery can be achieved for the aim of vaccination, anticancer therapy, and tissue repair.

At present, he has published 151 SCI papers, with 9,336 citations by others. Among them, in the past ten years, as the corresponding author, 85 SCI papers have been published in prestigious journals such as Nature, Nature Nanotechnology, Nature Biomedical Engineering, Science Translational Medicine, and Cell Host & Microbe, including 20 papers in the main editions and sub-editions of CNS (Cell, Nature, and Science). Four international invention patents and seven Chinese invention patents have been authorized. Three formulations have passed ethical approval and initiated Investigator-Initiated Trials (IIT) research. Awards include the SCEJ Award for Outstanding Asian Researcher and Engineer, the First Prize of Natural Science of the Chinese Society of Particles, and the Innovation Breakthrough Award in Life Medicine of Zhongyuan Union Cell & Gene Engineering Corporation, etc. The individual has presided over projects such as the Outstanding Young Scientist Fund of the National Natural Science Foundation of China, the National Key R & D Program, Strategic Priority Research Program Class C of the Chinese Academy of Sciences, and the Youth Team Program for Stable Support in Basic Research Fields of the Chinese Academy of Sciences, etc. The individual also serves as a member of the Biochemical Engineering Committee of the Chinese Institute of Chemical Engineers, a member of the Professional Committee of Vaccine Basic Research of the China Vaccine Industry Association, etc. 

1. Tong Ye#, Zhouguang Jiao#, Xin Li#, Zhanlong He, Yanyan Li, Fengmei Yang, Xin Zhao, Youchun Wang, Weijin Huang, Meng Qin, Yingmei Feng, Yefeng Qiu, Wenhui Yang, Lingfei Hu, Yaling Hu, Yu Zhai, Erqiang Wang, Di Yu, Shuang Wang, Hua Yue, Yishu Wang, Hengliang Wang*, Li Zhu*, Guanghui Ma*, Wei Wei*. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature. 2023, 624: 630-638.

2. Peilin Guo#, Wenjing Wang#, Qian Xiang, Chao Pan, Yefeng Qiu, Tingting Li, Dongfang Wang, Jian Ouyang, Rongrong Jia, Min Shi, Yugang Wang, Junxia Li, Jiale Zou, Yuan Zhong, Jiawei Zhao, Diwei Zheng, Yimin Cui*, Guanghui Ma*, Wei Wei*. Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis, Cell Host & Microbe, 2024, 32: 1502-1518.

3. Han Bao#, Ying Tian#, Haixin Wang, Tong Ye, Shuang Wang, Jiawei Zhao, Yefeng Qiu, Jian Li, Chao Pan, Guanghui Ma*, Wei Wei*, Yong Tao*, Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases. Nature Biomedical Engineering. 2024, 8: 1436-1452.

4. Xiaohong Chen#, Shuang Wang#, Yuxuan Chen#, Huhu Xin, Shuaishuai Zhang, Di Wu, Yanan Xue, Menglei Zha, Hongjun Li, Kai Li, Zhen Gu, Wei Wei*, Yuan Ping*. Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours. Nature Nanotechnology. 2023, 18: 933-944.

5. Xiaoming Hu#, Shuang Wang#, Shaotong Fu#, Meng Qin, Chengliang Lyu, Zhaowen Ding, Yan Wang, Yishu Wang, Dongshu Wang, Li Zhu, Tao Jiang, Jing Sun, Hui Ding, Jie Wu, Lingqian Chang, Yimin Cui, Xiaocong Pang, Youchun Wang, Weijin Huang, Peidong Yang, Limin Wang*, Guanghui Ma*, Wei Wei*. Intranasal mask for protecting the respiratory tract against viral aerosols. Nature Communications. 2023, 14: 8398.

6. Jiaqi Meng#, Yanlin Lv#, Weier Bao#, ZihuiMeng, Shuang Wang, Yuanbin Wu, Shuping Li, Zhouguang Jiao, Zhiyuan Tian*, Guanghui Ma*, Wei Wei*. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nature Communications. 2023, 14: 4505.

7. Changlong Wang#, Wei Zhang#, Yanjie He#, Zirui Gao, Liyuan Liu, Siyao Yu, Yuxing Hu, Shuang Wang, Chaochao Zhao, Hui Li, Jinan Shi, Wu Zhou, Feng Li, Hua Yue, Yuhua Li*, Wei Wei*, Guanghui Ma*, Ding Ma*. Ferritin-based targeted delivery of arsenic to diverse leukemia types confers strong anti-leukemia therapeutic effects. Nature Nanotechnology. 2021, 16: 1413-1423.

8. Shuang Wang, Feng Li, Tong Ye, Jianghua Wang, Chengliang Lyu, Shuang Qing, Zhaowen Ding, Xiaoyong Gao, Rongrong Jia, Di Yu, Jun Ren, Wei Wei*, Guanghui Ma*. Macrophage-tumor chimeric exosomes accumulate in both lymph node and tumor for activation of immune response and tumor microenvironment. Science Translational Medicine. 2021, 13: eabb6981.

9. Ying Tian#, Fan Zhang#, Yefeng Qiu, Shuang Wang, Feng Li, Jiawei Zhao, Chao Pan, Yong Tao*, Di Yu*, Wei Wei*. Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells. Nature Biomedical Engineering. 2021, 5: 968-982.

10. Xiaoling Xie#, Yuxing Hu#, Tong Ye#, Yiran Chen, Lijuan Zhou, Feng Li, Xiaobo Xi, Shuang Wang, Yanjie He, Xiaoyong Gao, Wei Wei*, Guanghui Ma*, Yuhua Li*. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nature Biomedical Engineering. 2021, 5: 414-428.